FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome

Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Annette Stein(Universität Hamburg), Fabian Maximilian Meinert(Charité - Universitätsmedizin Berlin), A. Florschütz(Städtisches Klinikum Dessau), Franziska Cygon(University Hospital in Halle), Arndt Vogel(Princess Margaret Cancer Centre), Stephan Kanzler(Leopoldina Krankenhaus Schweinfurt), Carla Hannig(Praxis für Hämatologie und Onkologie), Christian Junghanß(University of Rostock), Ulrich Kaiser(University of Applied Sciences Landshut), Benjamin Garlipp(University Hospital Magdeburg)
Annals of Oncology
June 1, 2018
10.1093/annonc/mdy149.022
Cited by 15

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k